Rapid7 Appoints Former SanDisk CFO, Judy Bruner, to its

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Rapid7 Appoints Former SanDisk CFO, Judy Bruner, to its Board of Directors

BOSTON, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD ), a leading provider of security data and analytics solutions, today announced that it has appointed Judy Bruner to its Board of Directors, effective October 31, 2016. She has also joined the board’s audit committee.

“I am pleased to welcome Judy Bruner to the Rapid7 board,” said Alan Matthews, chairman of the Board of Directors.  “Judy has an impressive track record of operational excellence as both a company executive and board member.  She brings a wealth of experience that will help us to capitalize on the tremendous market opportunity that lies ahead.”

Ms. Bruner served as executive vice president and chief financial officer of SanDisk Corporation from June 2004 until the company’s acquisition by Western Digital Corporation earlier this year. Previously, she was senior vice president and chief financial officer of Palm, Inc., from September 1999 until June 2004. She also held financial management positions at 3Com Corporation, Ridge Computers, and Hewlett-Packard Company. Ms. Bruner holds a BA in Economics from the University of California, Los Angeles, and an MBA from the University of Santa Clara.

Ms. Bruner has also served on a number of boards during her impressive career. She currently serves on the board of directors of Brocade Communications Systems Inc., Applied Materials Inc., and Varian Medical Systems Inc.

“Judy is a seasoned business executive with proven experience managing global enterprises,” said Corey Thomas, chief executive officer and president of Rapid7. “She is a valuable addition to our Board of Directors bringing financial and operational expertise that will be beneficial to Rapid7 and our shareholders. We are excited to have her leadership as we continue to scale our business and execute the Company’s long-term growth strategy.”

About Rapid7 Rapid7 is a leading provider of security data and analytics solutions that enable organizations to implement an active, analytics-driven approach to cyber security. We combine our extensive experience in security data and analytics and deep insight into attacker behaviors and techniques to make sense of the wealth of data available to organizations about their IT environments and users. Our solutions empower organizations to prevent attacks by providing visibility into vulnerabilities and to rapidly detect compromises, respond to breaches, and correct the underlying causes of attacks. Rapid7 is trusted by more than 5,600 organizations across over 100 countries, including 37% of the Fortune 1000. To learn more about Rapid7 or get involved in our threat research, visit www.rapid7.com .

Cautionary Language Concerning Forward-Looking Statements This press release includes forward-looking statements. All statements contained in this press release other than statements of historical facts, including, without limitation, statements relating to the Company’s growth strategy, delivering long-term value and the company’s future market opportunities, are forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks and uncertainties, including, without limitation, risks related to our rapid growth and ability to sustain our revenue growth rate, the ability of our products and professional services to correctly detect vulnerabilities, competition in the markets in which we operate, market growth, our ability to innovate and manage our growth, our ability to integrate acquired operations, our ability to operate in compliance with applicable laws as well as other risks and uncertainties set forth in the “Risk Factors” section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the quarterly period ended June 30, 2016 filed with the Securities and Exchange Commission on August 9, 2016, and subsequent reports that we file with the Securities and Exchange Commission.  Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, we cannot guarantee future results, levels of activity, performance, achievements or events and circumstances reflected in the forward-looking statements will occur. We are under no duty to update any of these forward-looking statements after the date of this press release to conform these statements to actual results or revised expectations, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact: Rapid7 Investor Relations Email: investors@rapid7.com Phone: +1 857 415 4419 Press Contact: Rachel E. Adam, Senior PR Manager Email: press@rapid7.com Phone: +1 857 415 4443

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 356

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 371

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 150

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 347

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 309

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 238

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 177

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 243

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Air Canada Navigates Operational Challenges Amid Storms

Updated Category News Views 205

Air Canada's Operational Challenges and Responses Air Canada has recently faced significant operational hurdles due to severe winter weather and an aircraft incident impacting its Toronto Pearson international hub. These challenges have necessitated a comprehensive update from the airline about its current status and ongoing recovery efforts. Recent Weather Impact on...

Continue Reading
Insight into Melexis' Ongoing Share Buy-Back Strategy

Updated Category News Views 128

Melexis Enhances Shareholder Value Through a Strategic Buyback Melexis, a leader in the semiconductor industry, has been actively engaging in a strategic share buy-back program aimed at bolstering shareholder value. This initiative, first announced on December 10, 2024, reflects the company's commitment to enhancing its stock's performance while also optimizing its...

Continue Reading
Value Line, Inc. Launches New Share Repurchase Initiative

Updated Category News Views 220

Value Line, Inc. Announces Stock Repurchase Program Value Line, Inc. (NASDAQ: VALU) recently revealed an exciting development for its shareholders: the Board of Directors has approved a share repurchase program that allows for the buyback of up to $2,000,000 worth of shares. This program comes into effect immediately and marks a significant move that replaces the previous...

Continue Reading
IsoEnergy Expands Stake in Premier American Uranium Inc. Assets

Updated Category News Views 154

IsoEnergy Enhances Investment in Premier American Uranium Inc. IsoEnergy Ltd. (NYSE American: ISOU) (TSX: ISO) has recently expanded its investment in Premier American Uranium Inc. by acquiring a significant number of common shares and warrants. This strategic move further establishes IsoEnergy’s commitment to capitalizing on the promising uranium market amid increasing...

Continue Reading
Texas Attorney General Takes Action Against Insulin Price Fixing

Updated Category News Views 70

Texas Attorney General's Lawsuit Against Insulin Price Fixing Texas Attorney General Ken Paxton has taken significant action by filing a lawsuit against several prominent insulin manufacturers and pharmacy benefit managers (PBMs). The lawsuit highlights allegations of a conspiracy to inflate insulin prices, affecting countless patients who rely on this vital medication....

Continue Reading